Scientists from Trinity College Dublin believe that the marvel molecule -- MCC950 -- could one day be used to treat a myriad of these diseases
Scientists at Trinity College Dublin have uncovered a marvel molecule that blocks a key driver of inflammatory diseases. The finding could meet a major unmet clinical need by inspiring new non-invasive treatments for arthritis, multiple sclerosis and Muckle-Wells syndrome, among a myriad of other inflammatory diseases.
In a study published this week in the world's leading preclinical medical journal Nature Medicine, the international research team led by Trinity and the University of Queensland Australia showed how the molecule MCC950 can suppress the 'NLRP3 inflammasome', which is an activator of the key process in inflammatory diseases.
Inflammasomes have been identified as promising therapeutic targets by researchers over the last decade. And now the discovery of MCC950's abilities represents a hugely significant development in the effort to find treatments for inflammatory diseases, for which current therapies are either highly ineffective or have major limitations.
Crucially, the finding also confirms that inflammatory diseases all share a common process, even though the part of the body becoming inflamed might differ.
Professor of Biochemistry at Trinity, Luke O'Neill, is the joint senior scientist behind the discovery. He said: "Drugs like aspirin or steroids can work in several diseases, but can have side effects or be ineffective. What we have found is a potentially transformative medicine, which targets what appears to be the common disease-causing process in a myriad of inflammatory diseases."
Dr Rebecca Coll, lead author on the paper, said: "MCC950 is blocking what was suspected to be a key process in inflammation. There is huge interest in NLRP3 both among medical researchers and pharmaceutical companies and we feel our work makes a significant contribution to the efforts to find new medicines to limit it."
Professor Matt Cooper, chemist and co-senior author from the University of Queensland's Institute for Molecular Bioscience (IMB), added: "MCC950 is able to be given orally and will be cheaper to produce than current protein-based treatments, which are given daily, weekly, or monthly by injection. Importantly, it will also have a shorter duration in the body, allowing clinicians to stop the anti-inflammatory action of the drug if the patient ever needed to switch their immune response back to 100% in order to clear an infection."
So far, the results have shown great promise for blocking multiple sclerosis in a model of that disease, as well as in sepsis, where in response to bacteria, potentially fatal blood poisoning occurs. However, the target for MCC950 is strongly implicated in diseases such as Alzheimer's disease, atherosclerosis, gout, Parkinson's disease and rheumatoid arthritis, which means it has the potential to treat all of these conditions.
Another disease where the new drug might have significant benefits is Muckle-Wells syndrome, which is a rare and severe auto-inflammatory disorder. Using blood samples from patients, the authors showed that MCC950 can block the rogue gene responsible for repeated inflammatory activation in sufferers.
Dr Dan Kastner of the National Institutes of Health USA, said: "MCC950 might well be a key addition to the options for treating Muckle-Wells syndrome and similar diseases."
Professor O'Neill added: "We are really excited about MCC950. We believe this has real potential to benefit patients suffering from several highly debilitating diseases, where there is currently a dire need for new medicines."
The study was a major collaboration between six institutions, including Trinity and the Universities of Queensland, Michigan, Massachusetts and Bonn.
The work in the O'Neill laboratory was supported by Science Foundation Ireland and the European Research Council. The research paper can be viewed here after the embargo has lifted: http://dx.
Thomas Deane | EurekAlert!
A novel socio-ecological approach helps identifying suitable wolf habitats
17.02.2017 | Universität Zürich
New, ultra-flexible probes form reliable, scar-free integration with the brain
16.02.2017 | University of Texas at Austin
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
20.02.2017 | Materials Sciences
20.02.2017 | Health and Medicine
20.02.2017 | Health and Medicine